All News
Filter News
Found 806,075 articles
-
Probo Medical Completes Acquisition of Davis Medical
11/16/2023
Probo Medical ("Probo"), a leading global provider of medical imaging equipment, parts, repair and service, announced the acquisition of Davis Medical Electronics, Inc. ("Davis Medical").
-
Momentum Biotechnologies and Axxam S.p.A. Announce Collaboration to Provide Unique Drug Discovery Solutions
11/16/2023
Axxam S.p.A. and Momentum Biotechnologies have announced a partnership to provide unique drug discovery solutions for biotechnology and pharmaceutical clients.
-
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
11/16/2023
Surmodics, Inc. announced today that 24-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB) was presented at the 50th annual VEITH Symposium in New York, New York.
-
Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation
11/16/2023
The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have approved Kanna Health's Investigational New Drug (IND) application and Clinical Trial Application (CTA), respectively, to start participant enrollment in a Phase 1 first-in-human clinical trial investigating the Safety and Pharmacokinetics of KH-001 Besylate (KH-001) in Healthy Male Subjects.
-
MANAMED Receives Expanded 510(k) Clearance for ManaFlexx 2
11/16/2023
The US Food and Drug Administration (FDA) has granted over-the-counter marketing clearance for the ManaFlexx 2®, an Electrical Stimulation (EMS) device, from MANAMED®, LLC.
-
First Human Clinical Study to Assess U.S. Department of Defense DNA Vaccine Candidate against Venezuelan Equine Encephalitis Delivered with PharmaJet Precision Delivery Systems.
11/16/2023
PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced the start of the first human clinical trial for a Venezuelan Equine Encephalitis (VEE) vaccine delivered with PharmaJet Precision Delivery Systems.
-
ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors
11/16/2023
ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, announced new data validating the reverse transcriptase (RT) of LINE-1, an abundant repeat element in the dark genome, as a novel target for drug discovery in autoimmune diseases, including lupus.
-
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
11/16/2023
Karuna Therapeutics, Inc. (NASDAQ: KRTX) today announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure.
-
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
11/16/2023
Merck (NYSE: MRK) today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
-
Siteman Cancer Center Begins Treatment with Latest Mevion Proton Therapy System
11/16/2023
Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System ® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center.
-
Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)
11/16/2023
Alentis Therapeutics announced today that the first patient has been dosed in a Phase 1/2 clinical trial of ALE.C04, a Claudin-1 (CLDN1) targeting investigational antibody for the treatment of CLDN1+ tumors.
-
Children's Hospital of Philadelphia Receives Multi-Million Dollar Gift from Holveck Family to Support Groundbreaking Osteosarcoma Research
11/16/2023
Children's Hospital of Philadelphia has received a $6.4 million gift from the family of Connor Boyle, a Central Bucks East High School graduate who died at age 18 from osteosarcoma.
-
Claris GenomiX announces licensing availability of ColoType, its patented mRNA-based Consensus Molecular Subtyping (CMS) assay for guiding colorectal cancer treatment decisions
11/16/2023
Claris GenomiX, Inc. announced today that ColoType, its patented mRNA-based cancer diagnostic, is available for exclusive licensing.
-
Complete Genomics opens $3.2 million manufacturing facility at its San Jose headquarters
11/16/2023
Complete Genomics, a pioneering genomic sequencing company, announced plans for the opening of a $3.2 million manufacturing facility within its headquarters in San Jose, California.
-
ACROBiosystems launches GM-grade DLL4 Protein to accelerate stem cell manufacturing
11/16/2023
ACROBiosystems recently announces the launch of GMP grade DLL4. GMP grade DLL4 is a recombinant, soluble form of Delta-like Ligand 4, or DLL4, that is one of the few products available on the market manufactured under GMP conditions.
-
Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles
11/16/2023
Micron Biomedical announced a $23.6 million grant from the Bill & Melinda Gates Foundation that will fund mass production of needle-free vaccines.
-
HSS (Hospital for Special Surgery) to Harness Surge in Artificial Intelligence Applications and Democratize High Quality Healthcare
11/16/2023
Hospital for Special Surgery, the world's leading musculoskeletal health institution, has received support from Schmidt Futures to advance its research and development efforts in artificial intelligence and machine learning.
-
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
11/16/2023
Alterity Therapeutics today announced promising new data related to ATH434 was presented at the Society for Neuroscience that took place November 11-15, 2023, in Washington, D.C.
-
InnerScope Hearing Technologies (OTC:INND) Launches its iHEAR Matrix OTC Hearing Aids in 4218 Walmart Stores
11/16/2023
InnerScope Hearing Technologies Inc. announced it is launching the iHEAR Matrix Rechargeable OTC Hearing Aids with Walmart as part of Walmart's OTC hearing aid display fixture located in 4,218 Walmart stores nationwide.
-
Stratasys Announces Changes to Board of Directors
11/16/2023
Stratasys Ltd. today announced that it has appointed Aris Kekedjian as an independent member of the Company’s Board of Directors, effective immediately.